UBS raised the firm’s price target on Gilead (GILD) to $96 from $70 and keeps a Neutral rating on the shares. The firm increased HIV PrEP and Livdelzi estimates, and sees potential for meaningful growth in Gilead’s HIV base business from PrEP market expansion with the launch of lenacapravir. However, with the shares up 30% over the last six months, and with the growth of the PrEP market still undefined, the think shares are appropriately valued currently, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $100 from $90 at Mizuho
- Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
- Gilead price target raised to $100 from $85 at Argus
- Gilead price target raised to $84 from $81 at RBC Capital
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer